DRTerHGAT:一种基于三元异构图注意力网络的药物重新定位方法
Hongjian He1, Jiang Xie1, Dingkai Huang1
1The School of Computer Engineering and Science, Shanghai University, Shanghai, China.
Journal of molecular graphics & modelling
|April 27, 2024
概括
这项研究引入了一种新的计算药物重定向方法DRTerHGAT,它集成了药物,蛋白质和疾病. 这种方法通过准确地提取蛋白质特征和分析复杂的关系来提高药物发现,以有效地重新使用药物,包括阿尔茨海默病.
科学领域:
- 计算生物学是一种计算生物学.
- 生物信息学是一种生物信息学.
- 药物发现 药物发现
背景情况:
- 药物重新利用通过确定现有药物的新用途来加速发展.
- 计算方法有效地选潜在的药物疾病关联.
- 将药物,蛋白质和疾病整合到一个统一的药物重新利用模式中是一项挑战.
研究的目的:
- 开发一种先进的计算药物重定向方法.
- 创建一个综合模型,整合药物,蛋白质和疾病.
- 提高识别潜在候选药物的准确性和效率.
主要方法:
- 提出了一个三元异质图注意力网络 (DRTerHGAT).
- 使用蛋白质语言模型和多任务自动编码器开发了一种新的蛋白质特征提取方法.
- 构建了一个具有多种关系类型的药物-蛋白质-疾病三元异质图.
- 利用图形卷积网络 (GCN) 和异质图形节点注意网络 (HGNA) 来进行特征提取.
主要成果:
- 与现有的先进方法及其变体相比,DRTerHGAT表现出优越的性能.
- 该方法有效地从药物,蛋白质和疾病中提取了深层特征.
- 验证了该模型在药物重用方面的有效性,特别强调其在阿尔茨海默病中的应用.
结论:
- DRTerHGAT提供了一种强大而有效的计算药物重定位方法.
- 蛋白质特征和复杂关系的整合显著增强了药物发现.
- 该模型对识别新型治疗策略充满希望,特别是在阿尔茨海默氏症等疾病中.
相关概念视频
Drug-Receptor Interaction: Antagonist
2.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.9K
Drug-Receptor Interactions
5.2K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.2K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Structure-Activity Relationships and Drug Design
708
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
708
Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K


